PL4346900T3 - Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego - Google Patents
Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnegoInfo
- Publication number
- PL4346900T3 PL4346900T3 PL22729540.9T PL22729540T PL4346900T3 PL 4346900 T3 PL4346900 T3 PL 4346900T3 PL 22729540 T PL22729540 T PL 22729540T PL 4346900 T3 PL4346900 T3 PL 4346900T3
- Authority
- PL
- Poland
- Prior art keywords
- tocopherol
- alpha
- ester
- risk
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000013898A IT202100013898A1 (it) | 2021-05-27 | 2021-05-27 | Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine |
| PCT/EP2022/063177 WO2022248269A1 (en) | 2021-05-27 | 2022-05-16 | Composition comprising an ester of alpha-tocopherol for reducing the risk of preterm birth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4346900T3 true PL4346900T3 (pl) | 2025-03-31 |
Family
ID=77801802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22729540.9T PL4346900T3 (pl) | 2021-05-27 | 2022-05-16 | Kompozycja zawierająca estr alfa-tokoferolu w celu zmniejszenia ryzyka porodu przedwczesnego |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12453714B2 (sr) |
| EP (1) | EP4346900B1 (sr) |
| AU (1) | AU2022283507A1 (sr) |
| BR (1) | BR112023024736A2 (sr) |
| CA (1) | CA3219732A1 (sr) |
| CL (1) | CL2023003488A1 (sr) |
| DK (1) | DK4346900T3 (sr) |
| ES (1) | ES3015526T3 (sr) |
| FI (1) | FI4346900T3 (sr) |
| GE (2) | GEP20247621B (sr) |
| HR (1) | HRP20250267T1 (sr) |
| HU (1) | HUE070246T2 (sr) |
| IT (1) | IT202100013898A1 (sr) |
| LT (1) | LT4346900T (sr) |
| MA (1) | MA64808B1 (sr) |
| MX (1) | MX2023013918A (sr) |
| PL (1) | PL4346900T3 (sr) |
| PT (1) | PT4346900T (sr) |
| RS (1) | RS66552B1 (sr) |
| SI (1) | SI4346900T1 (sr) |
| SM (1) | SMT202500076T1 (sr) |
| WO (1) | WO2022248269A1 (sr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3763075B2 (ja) | 1998-04-24 | 2006-04-05 | サンスター株式会社 | 歯周病の予防又は治療用の食品組成物、口腔用組成物及び医薬組成物 |
| WO2011150393A2 (en) | 2010-05-28 | 2011-12-01 | Bmg Hematology Llc | Methods for improving maternal and fetal health |
| CN101999426B (zh) * | 2010-09-25 | 2011-11-30 | 昆明医学院 | 孕妇营养饼干 |
| IL230419A0 (en) | 2013-05-23 | 2014-04-30 | Naveh Pharma 1996 Ltd | Products containing magnesium and their uses |
| LT3209294T (lt) * | 2014-10-22 | 2019-10-25 | Bio Lo Ga Srl | Farmacinė kompozicija, skirta panaudoti nosies gleivinės trofizmo padidinimui |
| JP2018522854A (ja) * | 2015-06-22 | 2018-08-16 | リポカイン インコーポレーテッド | 17−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法 |
| WO2017081725A1 (ja) * | 2015-11-09 | 2017-05-18 | 花王株式会社 | 口腔用組成物 |
| TWI912235B (zh) | 2017-12-01 | 2026-01-21 | 瑞士商雀巢製品股份有限公司 | 母體補充劑 |
-
2021
- 2021-05-27 IT IT102021000013898A patent/IT202100013898A1/it unknown
-
2022
- 2022-05-16 MX MX2023013918A patent/MX2023013918A/es unknown
- 2022-05-16 RS RS20250210A patent/RS66552B1/sr unknown
- 2022-05-16 WO PCT/EP2022/063177 patent/WO2022248269A1/en not_active Ceased
- 2022-05-16 DK DK22729540.9T patent/DK4346900T3/da active
- 2022-05-16 PT PT227295409T patent/PT4346900T/pt unknown
- 2022-05-16 GE GEAP202216392A patent/GEP20247621B/en unknown
- 2022-05-16 BR BR112023024736A patent/BR112023024736A2/pt unknown
- 2022-05-16 AU AU2022283507A patent/AU2022283507A1/en active Pending
- 2022-05-16 GE GEAP202316392A patent/GEAP202316392A/en unknown
- 2022-05-16 MA MA64808A patent/MA64808B1/fr unknown
- 2022-05-16 US US18/562,492 patent/US12453714B2/en active Active
- 2022-05-16 HU HUE22729540A patent/HUE070246T2/hu unknown
- 2022-05-16 PL PL22729540.9T patent/PL4346900T3/pl unknown
- 2022-05-16 CA CA3219732A patent/CA3219732A1/en active Pending
- 2022-05-16 HR HRP20250267TT patent/HRP20250267T1/hr unknown
- 2022-05-16 FI FIEP22729540.9T patent/FI4346900T3/fi active
- 2022-05-16 SI SI202230099T patent/SI4346900T1/sl unknown
- 2022-05-16 LT LTEPPCT/EP2022/063177T patent/LT4346900T/lt unknown
- 2022-05-16 SM SM20250076T patent/SMT202500076T1/it unknown
- 2022-05-16 ES ES22729540T patent/ES3015526T3/es active Active
- 2022-05-16 EP EP22729540.9A patent/EP4346900B1/en active Active
-
2023
- 2023-11-23 CL CL2023003488A patent/CL2023003488A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022283507A1 (en) | 2023-11-30 |
| GEP20247621B (en) | 2024-05-13 |
| EP4346900B1 (en) | 2025-01-29 |
| PT4346900T (pt) | 2025-02-19 |
| BR112023024736A2 (pt) | 2024-02-15 |
| SI4346900T1 (sl) | 2025-05-30 |
| DK4346900T3 (da) | 2025-02-17 |
| EP4346900A1 (en) | 2024-04-10 |
| HUE070246T2 (hu) | 2025-05-28 |
| RS66552B1 (sr) | 2025-03-31 |
| WO2022248269A1 (en) | 2022-12-01 |
| GEAP202316392A (en) | 2023-12-11 |
| MX2023013918A (es) | 2023-12-08 |
| LT4346900T (lt) | 2025-03-25 |
| MA64808B1 (fr) | 2025-02-28 |
| CA3219732A1 (en) | 2022-12-01 |
| CL2023003488A1 (es) | 2024-05-24 |
| SMT202500076T1 (it) | 2025-03-12 |
| HRP20250267T1 (hr) | 2025-04-11 |
| US20240261255A1 (en) | 2024-08-08 |
| FI4346900T3 (fi) | 2025-03-05 |
| IT202100013898A1 (it) | 2022-11-27 |
| ES3015526T3 (en) | 2025-05-06 |
| US12453714B2 (en) | 2025-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3352670B8 (en) | Method and system for assessing healing of tissue | |
| GB2585479B (en) | Reduction of the effects of latency for extended reality experiences | |
| PH12015501572A1 (en) | Veterinary supplements | |
| EP4281084A4 (en) | Compounds and methods for reducing Dux4 expression | |
| AU2010306870A8 (en) | Reducing the risk of pathological effects of traumatic brain injury | |
| EP4013889A4 (en) | SCHIZOPHRENIA RISK ASSESSMENT SYSTEM AND METHOD | |
| IL318706A (en) | Compositions and methods for inducing proptosis | |
| EP3479113A4 (en) | METHOD AND SYSTEM FOR REDUCING THE EFFECTS OF CROSSWAY OF PILLAR OUTLET | |
| SI4346900T1 (sl) | Sestava, ki vsebuje ester alfa-tokoferola za zmanjšanje tveganja prezgodnjega poroda | |
| GB202102798D0 (en) | Controller for an aircraft system | |
| EP3993464A4 (en) | Method for reducing nas signaling of lcs and lpp procedures | |
| SG11202007786WA (en) | Composition and composition for lowering blood pressure and/or reducing neutral fats | |
| EP3616705A4 (en) | COMPOSITION WITH AMOMUM VILLOSUM TO IMPROVE THE PREVENTION AND TREATMENT OF FATTY LIVER | |
| EP3621462A4 (en) | COMPOSITION FOR BETTER ABSORPTION OF COMPLEMENTS | |
| EP3366346A4 (en) | COSMETIC METHOD FOR REDUCING OR PREVENTING ACCUMULATION OF ADIPOSE TISSUE | |
| HK40091231A (en) | Method for determining risk of pre-term birth | |
| PL4308929T3 (pl) | Sposób diagnozy in vitro infekcji | |
| HK40085033A (en) | Tafoxiparin for the treatment of preeclampsia | |
| HK40110478A (en) | Compositions and methods for inhibiting the expression of tmigd2 | |
| SI3171873T1 (sl) | Sestavek, ki obsega ester alfa-tokoferola za preprečevanje in zdravljenje alergijskega rinitisa | |
| AU2021900576A0 (en) | Composition for the treatment of skin conditions such as eczema | |
| HK40102696A (en) | Compositions for the treatment of skin conditions | |
| AU2023902472A0 (en) | Methods and systems for assessing the presence of traumatic brain injury | |
| HK40116106A (en) | Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead | |
| GB202210304D0 (en) | Composition comprising cannabidiol |